BLA 761104 · Innate Pharma
Lumoxiti
Moxetumomab Pasudotox-Tdfk · Injection
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Aug 20, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Sep 13, 2018
Approved uses
1
Original approval plus efficacy supplements
Registered trials
14
1 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 13, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelMedication GuideLetter
1 products under this application
- LUMOXITI · MOXETUMOMAB PASUDOTOX-TDFK 1MG/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Moxetumomab Pasudotox" as an intervention, any sponsor and status, largest first.
MedImmune LLCAstraZeneca (AZN)
NCT00077493 · 95 participants (planned) · Start Jan 2004 · Primary completion Oct 2008
Drug: BL22 immunotoxin · For: Leukemia; Lymphoma
Sites: Bethesda, Maryland
- Moxetumomab Pasudotox for Advanced Hairy Cell LeukemiaPivotal-lookingCompleted
MedImmune LLCAstraZeneca (AZN)
NCT01829711 · 80 participants · Start Apr 29, 2013 · Primary completion May 24, 2017
Drug: Moxetumomab pasudotox; IV Bag Protectant for Moxetumomab pasudotox · For: Leukemia, Hairy Cell
Sites: Duarte, California; Los Angeles, California; Miami, Florida · 34 sites in all
MedImmune LLCAstraZeneca (AZN)
NCT00659425 · 57 participants · Start Sep 2008 · Primary completion Dec 2014
Drug: CAT-8015 (Moxetumomab Pasudotox); CAT-8015 (Moxetumomab Pasudotox) and 8 more · For: Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma
Sites: Los Angeles, California; Bethesda, Maryland; Boston, Massachusetts · 5 sites in all
- Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance DiseaseStatus unknown
Cambridge Antibody TechnologyAcademic, hospital or other
NCT00457860 · 50 participants · Start Mar 2007
Drug: Immunotoxin therapy; CAT-8015 immunotoxin · For: Leukemia
Sites: Beverly Hills, California; Indianapolis, Indiana; Bethesda, Maryland · 4 sites in all
Cambridge Antibody TechnologyAcademic, hospital or other
NCT00515892 · 50 participants (planned) · Start Aug 2007
Drug: Immunotoxin therapy; CAT-8015 Immunotoxin · For: Leukemia; Non-Hodgkin's Lymphoma; NHL
Sites: Beverly Hills, California; Bethesda, Maryland; Lodz, Poland
MedImmune LLCAstraZeneca (AZN)
NCT00587015 · 50 participants (planned) · Start Aug 2007 · Primary completion Mar 2008
Drug: CAT-8015 · For: Lymphoma
Sites: Beverly Hills, California; Bethesda, Maryland; Lodz, Poland
MedImmune LLCAstraZeneca (AZN)
NCT00586924 · 49 participants · Start May 10, 2007 · Primary completion May 6, 2015
Drug: Moxetumomab Pasudotox (CAT 8015); Moxetumomab Pasudotox (CAT 8015) and 4 more · For: Hairy Cell Leukemia
Sites: Stanford, California; Chicago, Illinois; Bethesda, Maryland · 4 sites in all
Cambridge Antibody TechnologyAcademic, hospital or other
NCT00462189 · 40 participants · Start Apr 2007
Drug: Immunotoxin therapy; CAT-8015 Immunotoxin · For: Leukemia; Hairy Cell Leukemia; HCL
Sites: Stanford, California; Chicago, Illinois; Bethesda, Maryland · 5 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
Kreitman RJ, Dearden C, Zinzani PL, et al. · J Hematol Oncol 2021 · Clinical Trial, Multicenter Study
- A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.
Short NJ, Kantarjian H, Jabbour E, et al. · Br J Haematol 2018 · Clinical Trial, Phase I, Letter
- Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
Wayne AS, Shah NN, Bhojwani D, et al. · Blood 2017 · Clinical Trial, Phase I, Multicenter Study
- Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia.
Shah NN, Bhojwani D, August K, et al. · Pediatr Blood Cancer 2020 · Clinical Trial, Phase II, Multicenter Study
- Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.
Kreitman RJ, Tallman MS, Robak T, et al. · J Clin Oncol 2012 · Clinical Trial, Phase I, Research Support, N.I.H., Intramural
- Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies.
Siddiqui R, Sardar M, Shahzad M, et al. · Clin Lymphoma Myeloma Leuk 2021 · Systematic Review
Sponsor: Innate Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.